Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T68251
(Former ID: TTDC00104)
|
|||||
Target Name |
Matrix metalloproteinase-2 (MMP-2)
|
|||||
Synonyms |
TBE-1; Matrix metalloproteinase 2; CLG4A; 72 kDa type IV collagenase; 72 kDa gelatinase
Click to Show/Hide
|
|||||
Gene Name |
MMP2
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Lung cancer [ICD-11: 2C25] | |||||
Function |
As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14. Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture.
Click to Show/Hide
|
|||||
BioChemical Class |
Peptidase
|
|||||
UniProt ID | ||||||
EC Number |
EC 3.4.24.24
|
|||||
Sequence |
MEALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFPGDVAPKTDKELAVQYLNTFYGC
PKESCNLFVLKDTLKKMQKFFGLPQTGDLDQNTIETMRKPRCGNPDVANYNFFPRKPKWD KNQITYRIIGYTPDLDPETVDDAFARAFQVWSDVTPLRFSRIHDGEADIMINFGRWEHGD GYPFDGKDGLLAHAFAPGTGVGGDSHFDDDELWTLGEGQVVRVKYGNADGEYCKFPFLFN GKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTMGGNAEGQPCKFPFRFQGT SYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETAMSTVGGNSEGAPCVFPFTFLGNKY ESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSQDPGAL MAPIYTYTKNFRLSQDDIKGIQELYGASPDIDLGTGPTPTLGPVTPEICKQDIVFDGIAQ IRGEIFFFKDRFIWRTVTPRDKPMGPLLVATFWPELPEKIDAVYEAPQEEKAVFFAGNEY WIYSASTLERGYPKPLTSLGLPPDVQRVDAAFNWSKNKKTYIFAGDKFWRYNEVKKKMDP GFPKLIADAWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLENQSLKSVKFGSIKSDWLGC Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
HIT2.0 ID | T80GUN |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
1 | Prinomastat | Drug Info | Approved | Lung cancer | [2], [3] | |
Clinical Trial Drug(s) | [+] 4 Clinical Trial Drugs | + | ||||
1 | Epigallocatechin gallate | Drug Info | Phase 3 | Hepatic fibrosis | [4], [5], [6], [7] | |
2 | Marimastat | Drug Info | Phase 3 | Pancreatic cancer | [8], [9] | |
3 | Metastat | Drug Info | Phase 1 | Acne vulgaris | [10], [11] | |
4 | Neovastat | Drug Info | Phase 1 | Renal cell carcinoma | [12] | |
Discontinued Drug(s) | [+] 8 Discontinued Drugs | + | ||||
1 | BMS 275291 | Drug Info | Discontinued in Phase 3 | Kaposi sarcoma | [13] | |
2 | Tanomastat | Drug Info | Discontinued in Phase 3 | Osteoarthritis | [14], [15] | |
3 | Galarubicin | Drug Info | Discontinued in Phase 2 | Solid tumour/cancer | [16] | |
4 | GM6001 | Drug Info | Discontinued in Phase 2 | Corneal ulcer | [17] | |
5 | RS-130830 | Drug Info | Discontinued in Phase 2 | Hepatitis C virus infection | [18] | |
6 | BB-1101 | Drug Info | Terminated | Multiple sclerosis | [20] | |
7 | BB-3644 | Drug Info | Terminated | Solid tumour/cancer | [21] | |
8 | CDP-845 | Drug Info | Terminated | Solid tumour/cancer | [22] | |
Preclinical Drug(s) | [+] 1 Preclinical Drugs | + | ||||
1 | RO-26-2853 | Drug Info | Preclinical | Solid tumour/cancer | [19] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Inhibitor | [+] 55 Inhibitor drugs | + | ||||
1 | Prinomastat | Drug Info | [1], [23], [24], [25], [26] | |||
2 | Epigallocatechin gallate | Drug Info | [27] | |||
3 | Marimastat | Drug Info | [28], [29], [30], [26] | |||
4 | Metastat | Drug Info | [31] | |||
5 | Neovastat | Drug Info | [32], [33], [34] | |||
6 | PMID29130358-Compound-Figure10(2a) | Drug Info | [35] | |||
7 | PMID29130358-Compound-Figure11(3) | Drug Info | [35] | |||
8 | PMID29130358-Compound-Figure13(4) | Drug Info | [35] | |||
9 | PMID29130358-Compound-Figure16(9a) | Drug Info | [35] | |||
10 | PMID29130358-Compound-Figure16(9b) | Drug Info | [35] | |||
11 | PMID29130358-Compound-Figure16(9c) | Drug Info | [35] | |||
12 | PMID29130358-Compound-Figure18(14) | Drug Info | [35] | |||
13 | PMID29130358-Compound-Figure18(14a) | Drug Info | [35] | |||
14 | PMID29130358-Compound-LonimacranthoideVII | Drug Info | [35] | |||
15 | PMID29130358-Compound-SB-3CT | Drug Info | [35] | |||
16 | BMS 275291 | Drug Info | [13], [36], [37], [26] | |||
17 | Tanomastat | Drug Info | [38], [39], [40], [26] | |||
18 | Galarubicin | Drug Info | [41] | |||
19 | GM6001 | Drug Info | [42] | |||
20 | RS-130830 | Drug Info | [43] | |||
21 | RO-26-2853 | Drug Info | [19] | |||
22 | BB-1101 | Drug Info | [44] | |||
23 | BB-3644 | Drug Info | [26], [21] | |||
24 | L-696418 | Drug Info | [46] | |||
25 | SC-44463 | Drug Info | [47] | |||
26 | (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid | Drug Info | [48] | |||
27 | 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid | Drug Info | [49] | |||
28 | 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide | Drug Info | [50] | |||
29 | 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid | Drug Info | [51] | |||
30 | 3-(4-Phenylethynylbenzoyl)nonanoic acid | Drug Info | [51] | |||
31 | 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid | Drug Info | [51] | |||
32 | 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione | Drug Info | [52] | |||
33 | 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione | Drug Info | [52] | |||
34 | 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione | Drug Info | [52] | |||
35 | 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione | Drug Info | [52] | |||
36 | Cis-2-aminocyclohexylcarbamoylphosphonic acid | Drug Info | [53] | |||
37 | Clinopodic acid C | Drug Info | [54] | |||
38 | Folate gamma-hydroxamic acid | Drug Info | [55] | |||
39 | Folate gamma-L-proline-hydroxamic acid | Drug Info | [55] | |||
40 | IK-862 | Drug Info | [56] | |||
41 | Lithospermic acid | Drug Info | [54] | |||
42 | Methotrexate gamma-hydroxamic acid | Drug Info | [55] | |||
43 | Methotrexate gamma-L-proline-hydroxamic acid | Drug Info | [55] | |||
44 | MMI270 | Drug Info | [57] | |||
45 | N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide | Drug Info | [50] | |||
46 | N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide | Drug Info | [58] | |||
47 | N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) | Drug Info | [58] | |||
48 | PD-169469 | Drug Info | [59] | |||
49 | PNU-107859 | Drug Info | [60] | |||
50 | Ro-37-9790 | Drug Info | [61] | |||
51 | Roche 28-2653 | Drug Info | [62] | |||
52 | SC-74020 | Drug Info | [63] | |||
53 | SR-973 | Drug Info | [64] | |||
54 | UK-356618 | Drug Info | [47] | |||
55 | [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid | Drug Info | [50] | |||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | CDP-845 | Drug Info | [45] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: SC-74020 | Ligand Info | |||||
Structure Description | SOLUTION STRUCTURE OF A CATALYTIC DOMAIN OF MMP-2 COMPLEXED WITH SC-74020 | PDB:1HOV | ||||
Method | Solution NMR | Resolution | N.A. | Mutation | No | [65] |
PDB Sequence |
MYNFFPRKPK
10 WDKNQITYRI20 IGYTPDLDPE30 TVDDAFARAF40 QVWSDVTPLR50 FSRIHDGEAD 60 IMINFGRWEH70 GDGYPFDGKD80 GLLAHAFAPG90 TGVGGDSHFD100 DDELWTNTSA 110 NYSLFLVAAH120 EFGHAMGLEH130 SQDPGALMAP140 IYTYTKNFRL150 SQDDIKGIQE 160 LYG
|
|||||
|
VAL42
3.261
GLY81
3.397
LEU82
2.566
LEU83
2.083
ALA84
2.131
HIS85
2.071
ALA86
3.635
PHE115
3.072
LEU116
2.596
VAL117
3.617
ALA119
3.606
HIS120
1.872
GLU121
1.987
HIS124
2.612
HIS130
2.784
PRO134
4.277
|
|||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Leukocyte transendothelial migration | hsa04670 | Affiliated Target |
|
Class: Organismal Systems => Immune system | Pathway Hierarchy | ||
GnRH signaling pathway | hsa04912 | Affiliated Target |
|
Class: Organismal Systems => Endocrine system | Pathway Hierarchy | ||
Estrogen signaling pathway | hsa04915 | Affiliated Target |
|
Class: Organismal Systems => Endocrine system | Pathway Hierarchy | ||
Relaxin signaling pathway | hsa04926 | Affiliated Target |
|
Class: Organismal Systems => Endocrine system | Pathway Hierarchy |
Degree | 23 | Degree centrality | 2.47E-03 | Betweenness centrality | 1.50E-03 |
---|---|---|---|---|---|
Closeness centrality | 2.38E-01 | Radiality | 1.42E+01 | Clustering coefficient | 1.42E-01 |
Neighborhood connectivity | 3.22E+01 | Topological coefficient | 7.49E-02 | Eccentricity | 12 |
Download | Click to Download the Full PPI Network of This Target | ||||
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-regulating Transcription Factors | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation | ||||||
Target QSAR Model |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45. | |||||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6505). | |||||
REF 3 | Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108. | |||||
REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7002). | |||||
REF 5 | The green tea polyphenol (2)-epigallocatechin-3-gallate (EGCG) is not a beta-secretase inhibitor. Bioorg Med Chem Lett. 2012 Feb 1;22(3):1408-14. | |||||
REF 6 | Epigallocatechin gallate modulates CYP450 isoforms in the female Swiss-Webster mouse. Toxicol Sci. 2003 Dec;76(2):262-70. | |||||
REF 7 | Prolyl endopeptidase inhibitors from green tea. Arch Pharm Res. 2001 Aug;24(4):292-6. | |||||
REF 8 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5220). | |||||
REF 9 | Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004 Dec 1;22(23):4683-90. | |||||
REF 10 | ClinicalTrials.gov (NCT00001683) A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer. U.S. National Institutes of Health. | |||||
REF 11 | A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res. 2004 Oct 1;10(19):6512-21. | |||||
REF 12 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||||
REF 13 | Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8. | |||||
REF 14 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6468). | |||||
REF 15 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010243) | |||||
REF 16 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004410) | |||||
REF 17 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001387) | |||||
REF 18 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010620) | |||||
REF 19 | Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. | |||||
REF 20 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006361) | |||||
REF 21 | A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br J Cancer. 2004 Feb 23;90(4):800-4. | |||||
REF 22 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006498) | |||||
REF 23 | Inhibition of gelatinase activity reduces neural injury in an ex vivo model of hypoxia-ischemia. Neuroscience. 2009 Jun 2;160(4):755-66. | |||||
REF 24 | Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat. J Neuroinflammation. 2008 Aug 11;5:34. | |||||
REF 25 | Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediat... Mol Cell Biol. 2008 Aug;28(15):4896-914. | |||||
REF 26 | Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. | |||||
REF 27 | Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4. | |||||
REF 28 | Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. | |||||
REF 29 | Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 2009 Feb;15(2):RA32-40. | |||||
REF 30 | Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69-75. | |||||
REF 31 | Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72. | |||||
REF 32 | Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5. | |||||
REF 33 | Neovastat (AE-941) inhibits the airway inflammation and hyperresponsiveness in a murine model of asthma. J Microbiol. 2005 Feb;43(1):11-6. | |||||
REF 34 | The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol. 2002 Feb;20(2):299-303. | |||||
REF 35 | Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. | |||||
REF 36 | Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer. 2004 Dec;46(3):361-8. | |||||
REF 37 | Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol. 2005 Apr 20;23(12):2831-9. | |||||
REF 38 | Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:44-6. | |||||
REF 39 | Conflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth J Natl Cancer Inst. 2006 Jun 7;98(11):726-7. | |||||
REF 40 | A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surg... Gynecol Oncol. 2006 Aug;102(2):300-8. | |||||
REF 41 | Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix m... Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31. | |||||
REF 42 | Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59. | |||||
REF 43 | Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6. | |||||
REF 44 | Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8. | |||||
REF 45 | Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999 Feb;1(2):117-29. | |||||
REF 46 | Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995). | |||||
REF 47 | A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. | |||||
REF 48 | The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. | |||||
REF 49 | Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3096-100. | |||||
REF 50 | Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. | |||||
REF 51 | Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. | |||||
REF 52 | Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. | |||||
REF 53 | Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic mat... J Med Chem. 2008 Mar 13;51(5):1406-14. | |||||
REF 54 | Matrix metalloproteinase-2 inhibitors from Clinopodium chinense var. parviflorum. J Nat Prod. 2009 Aug;72(8):1379-84. | |||||
REF 55 | Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. | |||||
REF 56 | Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7. | |||||
REF 57 | Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6. | |||||
REF 58 | Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5. | |||||
REF 59 | Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem. 2006 Feb 9;49(3):923-31. | |||||
REF 60 | A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics s... J Med Chem. 2004 Jun 3;47(12):3065-74. | |||||
REF 61 | 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997). | |||||
REF 62 | The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96. | |||||
REF 63 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
REF 64 | Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. | |||||
REF 65 | Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor. Biochim Biophys Acta. 2002 Jul 29;1598(1-2):10-23. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.